| abstract |
The present application discloses a product comprising (i) as a first component vemurafenib, and (ii) as a second component an MDM2 inhibitor selected from compounds (II) or (III), or a pharmaceutically acceptable salt thereof, for the sequential or concomitant use in the treatment of proliferative diseases, such as cancer, involving b-Raf V600 mutant positive tumor. |